The expansion of the dermatology sector is largely driven by a renewed focus on unmet medical needs in rare and chronic conditions. The Hidradenitis Suppurativa HS Treatment market growth is particularly evident in the biologics segment, where prescription rates have surged by over 20% in recent years. This momentum is supported by better insurance coverage and the introduction of patient support programs that make expensive therapies more accessible.

Moreover, the rise of "Skin of Color" dermatology has brought much-needed attention to how HS affects diverse populations. By addressing ethnic disparities in care, the medical community is broadening the reach of modern treatments. This inclusive approach not only improves patient outcomes but also drives the overall expansion of the global healthcare infrastructure.

FAQ:

• Q: Why is the HS market growing so fast?

• A: Increased awareness, better diagnostic tools, and the approval of new biologic therapies are the main drivers.